The professional exchange event 'Hundred Enterprises Walk into Haibu' was successfully held!

On May 19, 2021, the large-scale professional visit and exchange event "Walking into Haibu" was successfully held, organized by Beijing Haibu Pharmaceutical Technology Co., Ltd. and co-organized by Qiantuhui Pharmaceutical Technology (Beijing) Co., Ltd.Experts, teachers, and representatives from hundreds of domestic pharmaceutical companies visited Haibu to engage in in-depth exchanges around multiple thematic reports, jointly discussing industry dynamics, hot topics, and business cooperation models.

Sharing and exchange site

Speaker: Zhang Lin, Deputy General Manager of Haibu Pharmaceutical
Report theme: "Haibu Pharmaceutical - A Trusted Partner for Drug R&D"

Looking back on 16 years of development,Haibu Pharmaceutical has always focused on "chemical drug R&D" as its core capability, providing clients with full-chain CRO services, regulatory review related to active pharmaceutical ingredients (APIs), customized intermediate R&D, and drug import-export services.. The Haibu team possesses comprehensive project management capabilities from project evaluation, patent strategy design, preclinical research, clinical trial management to drug registration until product market qualification is obtained. The R&D products cover multiple therapeutic areas including anti-tumor, anti-depression, anti-epilepsy, anti-anxiety, cardiovascular and cerebrovascular diseases, digestive system disorders, respiratory system issues among others. A strict and effective quality and compliance management system centered on quality and customer-oriented project management processes as well as information technology and data security management systems have gained recognition and support from clients. After years of accumulation, good cooperative relationships have been established with numerous well-known domestic and foreign pharmaceutical enterprises.

The report also shared experiences with guests through some mature projects such as Brilinta (ticagrelor), Relugolix (Relugolix), Ibrutinib (Ibrutinib), communicating the R&D achievements of Haibu Pharmaceutical based on project focus. Haibu has completed over 100 technology transfers to Chinese pharmaceutical companies, obtained more than 70 various approvals and filed over 30 patents. More than 20 series of products have achieved commercial production and for three consecutive years has been recognized as one of the top 20 pharmaceutical R&D companies in China.

Speaker: Liu Zhijian, Assistant General Manager of the DDS Division at Boteng Co., Ltd.
Report theme: "Boteng CDMO One-stop Service Platform Empowering Generic Drug MAH Business Development"

Chongqing Boteng Pharmaceutical Technology Co., Ltd. was established in 2005. It mainly provides customized R&D and production services for chemical APIs, chemical formulations and biological drugs needed throughout the entire lifecycle from early clinical research to drug market launch for global pharmaceutical companies and new drug research institutions. Its R&D centers are located across China (Chongqing, Chengdu, Shanghai, Yichun, Suzhou Hong Kong), the United States Belgium Switzerland UK with five R&D centers one J-Star facility three production bases adhering to international first-class quality safety standards for various production operational activities while maintaining a strict intellectual property management system providing clients with a safe reliable stable supply chain.

The comprehensive production engineering capabilities of APIs combined with conventional complex formulation technical platforms along with a customer-centric project management philosophy provide clients with one-stop service throughout their lifecycle empowering generic drug MAH business since 2017 nearly fifty API formulation projects have been implemented in collaboration with CROs pharmaceutical companies CSOs. Boteng is committed to becoming the most open innovative reliable pharmaceutical service platform globally allowing good drugs to benefit the public sooner.

Speaker: Dr. Xiang Song，Director of Synthesis at Haibu Pharmaceutical
Report theme: "Research Control Quality of Active Pharmaceutical Ingredients - Basic Strategies Based on QBD"

Dr. Xiang briefly introduced the basic concepts of QbD along with key elements in API development under QbD principles outlined in ICH Q11; he also illustrated two examples based on generic drug development experience demonstrating strategies based on QbD through reasonable experimental design for quality control of APIs.

Speaker: Dr. Yu Fanglin，Director of Formulation at Haibu Pharmaceutical
"Pharmacokinetics of Controlled Release Formulations"

. Dr. Yu systematically introduced pharmacokinetics related to controlled release formulations explaining pharmacokinetics bioavailability bioequivalence correlations between formulations inside outside body which helps deepen our understanding regarding theoretical foundations bioavailability effectiveness concepts methods concerning controlled release formulations; it aids formulation researchers studying prescription process designs based upon absorption mechanisms within body; it supports studies correlating internal external factors based upon pharmacokinetic theories computer software assistance.

Speaker: Dr.Wang Zhengguo，Senior Consultant Chemical Drug Development at Haibu Pharmaceuticals
Report Theme:"PEGylation Of Small Molecule Chemical Drugs"

Dr.Wang systematically introduced mechanisms technological advancements market advantages PEGylation drugs detailed challenges core technologies small molecule chemical drugs PEGylation representative examples showcasing advantages practicality PEGylation chemical drugs serves shortcut improvement innovation.

Speaker: Dr.Zhang Xu，Deputy General Manager at Haibu Pharmaceuticals
Report Theme:"Methods Strategies Pharmaceutics Research Innovative Drugs"

Innovative pharmaceutics research characterized gradual phase uncertainty breadth depth continuously advancing alongside clinical trials while pharmaceutics serves material basis quality foundation clinical evaluations small molecule studies play crucial role new drug investigations.Risk being core throughout innovative drug development lifecycle necessitates objective assessments changes potential impacts product quality safety trial results connectivity.CMC development speed remains central theme harmonizing quality delivery cost correctly evaluating compound prospects conducting comprehensive evaluations pharmacology toxicology interrelations constitutes key success factors CMC development.

Visit site

Guests accompanied by staff visited the research office building at Haibu Pharmaceuticals' Hai Industry Park where guides provided detailed introductions regarding synthesis formulation analysis stability testing experimental materials other experimental management areas relevant advanced laboratory equipment functions allowing guests intuitively understand rational efficient laboratory construction layout showcasing reasonable allocation resources across three major platforms raw materials formulations innovations high-level capabilities undertaking both research business instilling confidence guests towards services products offered by haibo pharmaceuticals.

The 2021 'Walk into Haibu' event concluded successfully with laughter and joy during the dinner. The attending guests gained a more comprehensive understanding of Haibu Pharmaceutical. The valuable sharing of academic experiences and significant project recommendations made the guests feel that the event was very worthwhile, and they look forward to deeper and closer cooperation with Haibu Pharmaceutical to jointly promote industry development. Driven by technology for growth, Haibu Pharmaceutical will adhere to the principles of integrity, professionalism, cooperation, and win-win outcomes, continuously serving customers with professional capabilities and a dedicated attitude, becoming the most trustworthy partner in drug research and development.